Aquestive Therapeutics宣布，已向美国食品药品监督管理局（FDA）重新提交了Anaphylm™（二丁肾上腺素）舌下膜的新药申请（NDA）。这一举动标志着该公司在推进这款创新药物上市进程中迈出了关键一步。Anaphylm™作为一种舌下给药的肾上腺素制剂，旨在为严重过敏反应患者提供一种更为便捷、无针的急救选择。
Aquestive Therapeutics宣布，已向美国食品药品监督管理局（FDA）重新提交了Anaphylm™（二丁肾上腺素）舌下膜的新药申请（NDA）。这一举动标志着该公司在推进这款创新药物上市进程中迈出了关键一步。Anaphylm™作为一种舌下给药的肾上腺素制剂，旨在为严重过敏反应患者提供一种更为便捷、无针的急救选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.